Literature DB >> 6176541

Detection of gamma interferon in the sera of patients with Behçet's disease.

S Ohno, F Kato, H Matsuda, N Fujii, T Minagawa.   

Abstract

The serum levels of interferon (IFN) in 58 patients with Behçet's disease were significantly higher than those in 79 normal controls (P less than 0.0001). The average IFN titer was 51.4 +/- 9.3 IU/ml in the patients and 5.9 +/- 1.1 IU/ml in the controls. The patients were then divided into two groups according to the stage of ocular disease. Forty-six patients in the ocular convalescent stage had higher IFN levels (61.3 +/- 11.2 IU/ml) than did 12 patients in the exacerbation stage (13.2 +/- 3.0 IU/ml). Moreover, the kinetics of the IFN level in the circulation of seven patients showed a significant decrease of IFN in the exacerbation stage. IFN activity in sera from patients was destroyed by acid treatment and heating at 56 degrees C for 30 min and was not neutralized with anti-human IFN-alpha and -beta sera. In addition, it was demonstrated that vesicular stomatitis virus inhibitors detected in sera from both the patients and the controls had no effect on our IFN assay. Therefore, antiviral activity detected in sera of patients seems to be due to gamma interferon (IFN-gamma). IFN-gamma may play a significant role in the pathophysiology of Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176541      PMCID: PMC351204          DOI: 10.1128/iai.36.1.202-208.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  [Some observations on uveitis in Japan, with special reference to Vogt-Koyanagi-Harada and Behçet diseases (author's transl)].

Authors:  S Sugiura
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1976-11-10

2.  Specific histocompatibility antigens associated with Behçet's disease.

Authors:  S Ono; E Nakayama; S Sugiura; K Itakura; K Aoki
Journal:  Am J Ophthalmol       Date:  1975-10       Impact factor: 5.258

3.  Production of interferon by immune lymphocytes exposed to herpes simplex virus-antibody complexes.

Authors:  T Fujibayashi; J J Hooks; A L Notkins
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

4.  Reduction of complement in Behçet's disease and drug allergy.

Authors:  K Shimada; M Kogure; T Kawashima; K Nishioka
Journal:  Med Biol       Date:  1974-08

5.  Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity.

Authors:  J S Youngner; S B Salvin
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

6.  HLA-Bw51 and Behçet's disease.

Authors:  S Ohno; T Asanuma; S Sugiura; A Wakisaka; M Aizawa; K Itakura
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

7.  Enzymatic induction of interferon production by galactose oxidase treatment of human lymphoid cells.

Authors:  F Dianzani; T M Monahan; A Scupham; M Zucca
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

Review 8.  Behçet disease (Behçet syndrome).

Authors:  T Shimizu; G E Ehrlich; G Inaba; K Hayashi
Journal:  Semin Arthritis Rheum       Date:  1979-05       Impact factor: 5.532

9.  Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen.

Authors:  M J Valle; A M Bobrove; S Strober; T C Merigan
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

10.  Regulatory effect of interferon on T cells in vitro.

Authors:  I Heron; K Berg; K Cantell
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

View more
  16 in total

1.  Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS).

Authors:  J Freysdottir; S Lau; F Fortune
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations?

Authors:  U Musabak; S Pay; H Erdem; I Simsek; A Pekel; A Dinc; A Sengul
Journal:  Rheumatol Int       Date:  2005-10-05       Impact factor: 2.631

3.  Cytotoxic T cells against herpes simplex virus in Behçet's disease.

Authors:  K Hamzaoui; A Kahan; K Ayed; M Hamza
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

4.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

5.  Cytokines in health and disease.

Authors:  L Borecký
Journal:  World J Microbiol Biotechnol       Date:  1992-12       Impact factor: 3.312

6.  Immunoreactive IFN-gamma in CSF in neurological disorders.

Authors:  R J Abbott; I Bolderson; P J Gruer; R C Peatfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-07       Impact factor: 10.154

Review 7.  Expression of the genes of interferons and other cytokines in normal and diseased tissues of man.

Authors:  M G Tovey
Journal:  Experientia       Date:  1989-06-15

8.  Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome.

Authors:  T H Bacon; F Ozbakir; C A Elms; A M Denman
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

9.  Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon.

Authors:  T W Chang; S McKinney; V Liu; P C Kung; J Vilcek; J Le
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Interferon system in patients with systemic juvenile chronic arthritis: in vivo and in vitro studies.

Authors:  T H Bacon; A de Vere-Tyndall; D A Tyrrell; A M Denman; B M Ansell
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.